Midcourse Review  >  Table of Contents  > Focus Area 14: Immunization and Infectious Diseases  >  Progress Quotient Chart

Figure 14-1. Progress Quotient Chart for Focus Area 14: Immunization and Infectious Diseases

Moved away from target Moved away from target Moved toward target Moved toward target Met target Met target

  Percent of targeted change achieved
14-1. Cases of vaccine-preventable diseases
(1998, 2003)
a. Congenital rubella syndrome: < 1 year Moved toward target
86% - Moved toward target
b. Diphtheria: < 35 years Met target 100% - Met target
c. Haemophilus influenzae type B: < 5 years Moved away from target 
-59% - Moved away from target
d. Hepatitis B: 2-18 years (1997, 2003) Moved toward target
81% - Moved toward target
e. Measles Moved toward target
57% - Moved toward target
f. Mumps Moved toward target
67% - Moved toward target
g. Pertussis: < 7 years Moved away from target 
-21% - Moved away from target
h. Polio: wild virus type Met target 100% - Met target
i. Rubella Moved toward target
98% - Moved toward target
j. Tetanus: < 35 years Moved toward target
57% - Moved toward target
k. Varicella: average annual number of cases, < 18 years (1999, 2001) Moved toward target
53% - Moved toward target
14-2. Cases of chronic hepatitis B infection: ≤ 2 years (1995, 2002) Moved toward target
63% - Moved toward target
14-3. Hepatitis B (1997, 2003)  
a. 19-24 years Moved toward target
58% - Moved toward target
b. 25-39 years Moved toward target
41% - Moved toward target
c. 40+ years Moved toward target
67% - Moved toward target
d. Injection drug users Moved toward target
75% - Moved toward target
e. Heterosexually active persons Moved toward target
61% - Moved toward target
f. Men who have sex with men Moved away from target 
-8% - Moved away from target
g. Occupationally exposed workers
Met target and increasingMet target and increasing
110% - Met target
14-4. Bacterial meningitis: 1-23 months (1998, 2002)
Met target and increasingMet target and increasing
114% - Met target
14-5. Invasive pneumococcal infections (1997, 2002)  
a. < 5 years
Met target and increasingMet target and increasing
171% - Met target
b. 65+ years Moved toward target
95% - Moved toward target
14-5. Invasive penicillin-resistant pneumococcal infections  
c. < 5 years
Met target and increasingMet target and increasing
110% - Met target
d. 65+ years
Moved away from target and decreasingMoved away from target and decreasing
-200% - Moved away from target
14-6. Hepatitis A (1997, 2003)
Met target and increasingMet target and increasing
125% - Met target
14-7. Meningococcal disease (1997, 2002)
Met target and increasingMet target and increasing
267% - Met target
14-8. Lyme disease (1992–96, 2002)
Moved away from target and decreasingMoved away from target and decreasing
-196% - Moved away from target
14-9. Hepatitis C (1997, 2003) Moved toward target
60% - Moved toward target
14-11. Tuberculosis (1998, 2003) Moved toward target
29% - Moved toward target
14-12. Curative therapy for tuberculosis (1996, 2000) Moved toward target
38% - Moved toward target
14-16. Invasive early onset group B streptococcal disease (1996, 2002)
Met target and increasingMet target and increasing
120% - Met target
14-17. Peptic ulcer hospitalizations (1998, 2002) Moved toward target
32% - Moved toward target
14-18. Antibiotics prescribed for ear infections: < 5 years (1996–97, 2001) Moved toward target
77% - Moved toward target
14-19. Antibiotics prescribed for the common cold
(1996–97, 2001) 		Moved toward target
55% - Moved toward target
14-20. ICU patients (1998, 2003)  
a. Catheter-associated urinary tract infection
Met target and increasingMet target and increasing
120% - Met target
b. Central line-associated bloodstream infection
Met target and increasingMet target and increasing
120% - Met target
Infants weighing 1,000 grams or less in NICUs  
d. Central line-associated bloodstream infection (1995–98, 2002)
Met target and increasingMet target and increasing
133% - Met target
14-22. Immunizations: 19-35 months (1998, 2003)  
a. DTaP vaccine: 4 doses Moved toward target
17% - Moved toward target
b. Haemophilus influenzae type B vaccine: 3 doses Met target 100+%Percent of target achieved cannot be calculated.The most recent value is 20.4%; the baseline value is 16.3%; the target value is 4.0%. - Met target
c. Hepatitis B vaccine: 3 doses
Met target and increasingMet target and increasing
167% - Met target
d. MMR vaccine: 1 dose Met target 100+%Percent of target achieved cannot be calculated.The most recent value is 20.1%; the baseline value is 16.0%; the target value is 4.0%. - Met target
e. Polio vaccine: 3 doses Met target 100+%Percent of target achieved cannot be calculated.The most recent value is 25.1%; the baseline value is 19.5%; the target value is 4.0%. - Met target
f. Varicella vaccine: 1 dose Moved toward target
89% - Moved toward target
g. PCV vaccine: 4 doses (2002, 2003) Moved toward target
14% - Moved toward target
14-23. Immunizations: day care (1997–98, 2001)  
a. DTaP coverage Met target 100% - Met target
b. MMR coverage
Met target and increasingMet target and increasing
117% - Met target
c. Polio vaccine coverage Met target 100% - Met target
14-24a. Fully immunized: 19-35 months (1998, 2002) Moved toward target
29% - Moved toward target
14-25. Childhood vaccine coverage tracked by  
a. Public health providers (1999, 2001) Moved toward target
40% - Moved toward target
b. Private providers (1999, 2001) Moved toward target
39% - Moved toward target
14-26. Children in population-based immunization registries (1999, 2002) Moved toward target
59% - Moved toward target
14-27. Immunizations: 13-15 years (1997, 2003)  
a. Hepatitis B vaccine: 3+ doses Moved toward target
79% - Moved toward target
b. MMR vaccine: 2+ doses
Met target and increasingMet target and increasing
400% - Met target
c. Tetanus-diphtheria booster: 1+ doses Met target 100+%Percent of target achieved cannot be calculated.The most recent value is 21.5%; the baseline value is 17.5%; the target value is 4.0%. - Met target
d. Varicella vaccine: 1+ doses Moved toward target
71% - Moved toward target
14-28. Hepatitis B vaccination coverage  
a. Long-term hemodialysis patients
(1995, 2001)		 Moved toward target
46% - Moved toward target
b. Men who have sex with men
(1994–99, 1998–2000)		 Moved toward target
8% - Moved toward target
c. Occupationally exposed workers
(1995, 2003)		 Moved toward target
31% - Moved toward target
14-29. Noninstitutionalized: 65+ years (1998, 2003)  
a. Influenza vaccination in past year Moved toward target
8% - Moved toward target
b. Pneumococcal vaccination ever received Moved toward target
23% - Moved toward target
Noninstitutionalized high-risk: 18-64 years  
c. Influenza vaccination in past year Moved toward target
6% - Moved toward target
d. Pneumococcal vaccination ever received Moved toward target
6% - Moved toward target
14-29. Institutionalized: 18+ years (1997, 1999)  
e. Influenza vaccination in past year Moved toward target
23% - Moved toward target
f. Pneumococcal vaccination ever received Moved toward target
20% - Moved toward target
14-30a. Vaccine-associated paralytic polio (1997, 2000) Met target 100% - Met target
14-30b. Febrile seizures following pertussis vaccination (1998, 2001)
Met target and increasingMet target and increasing
129% - Met target
14-31a. Active surveillance for vaccine safety (1999, 2000) Moved toward target
29% - Moved toward target

Notes:

Tracking data for objectives 14-10, 14-13, 14-14, 14-20c and e, 14-21, 14-22h, 14-23d through l, 14-24b, 14-29g, and 14-31b are unavailable. Objective 14-15 was deleted at the midcourse.

Years in parentheses represent the baseline data year and the most recent data year used to compute the percent of the Healthy People 2010 target achieved.

Equation expressing change between baseline data year and most recent data value to detemine percent of 2010 target achieved.


* Percent of target achieved cannot be calculated.
1 The most recent value is 94%; the baseline value is 93%; the target value is 90%.
2 The most recent value is 93%; the baseline value is 92%; the target value is 90%.
3 The most recent value is 92%; the baseline value is 91%; the target value is 90%.
4 The most recent value is 91%; the baseline value is 93%; the target value is 90%.

<<  Previous—Emerging Issues    |   Table of Contents   |   Next—Disparities Table: Race and Ethnicity   >>